Advances in Biomarker Research for Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The lack of early symptoms results in latestage detection and a high mortality rate. Currently, the only potentially curative approach for PC is surgical resection, which is often unsuccessful because the invasive and metastatic nature of the tumor masses makes their complete removal difficult. Consequently, patients suffer relapses from remaining cancer stem cells or drug resistance that eventually lead to death. To improve the survival rate, the early detection of PC is critical. Current biomarker research in PC indicates that a serum carbohydrate antigen, CA 19-9, is the only available biomarker with approximately 90% specificity to PC. However, the efficacy of CA 19-9 for assessing prognosis and monitoring patients with PC remains contentious. Thus, advances in technology and the detection of new biomarkers with high specificity to PC are needed to reduce the mortality rate of pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Iacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081 · cited 1×
“In addition to K-ras and TP53 mutations, the loss of p16 and DPC4 was also frequently detected in tumor tissue of PC patients and correlated with its clinical relevance [84, 90-93].”
BackgroundKrüger, M., Moser, M., Ussar, S., Thievessen, I., Luber, C. A., Forner, F., Schmidt, S., Zanivan, S., Fässler, R., & Mann, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.033 · Cited by 680 · cited 1×
“Current Technologies for Biomarker Research [202-212]”
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657
Epidemiology and risk factors for pancreatic cancer
Lowenfels, A. B., & Maisonneuve, P. (2006) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2005.10.001 · Cited by 635 · cited 1×
“In general, individuals diagnosed with diabetes or with a history of pancreatitis or chronic pancreatitis are at a risk for developing PC [1, 34-35].”
BackgroundZindy, F., Quelle, D. E., Roussel, M. F., & Sherr, C. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201178 · Cited by 574
Telomere Shortening Is Nearly Universal in Pancreatic Intraepithelial Neoplasia
van Heek, N. T., Meeker, A. K., Kern, S. E., Yeo, C. J., Lillemoe, K. D., Cameron, J. L., Offerhaus, G. J. A., Hicks, J. L., Wilentz, R. E., Goggins, M. G., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64432-x · Cited by 363
Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players
Kim, M. P., & Gallick, G. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2247 · Cited by 177
DPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma
Biankin, A. V., Morey, A. L., Lee, C.-S., Kench, J. G., Biankin, S. A., Hook, H. C., Head, D. R., Hugh, T. B., Sutherland, R. L., & Henshall, S. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.063 · Cited by 163 · cited 2×
“Based on the tumor progression model, multiple genetic alterations are involved in a step-wise manner in the development of PC and in most cases, genetic changes in the four genes – K-ras, CDKN2A/p16, TP53, and SMAD4/DPC4 were detected in the PC patients [5, 22, 82-86].”
BackgroundHarada, T., Chelala, C., Bhakta, V, Chaplin, T., Caulee, K., Baril, P., Young, B. D., & Lemoine, N. R. (2008) · Oncogene · doi:10.1038/sj.onc.1210832 · Cited by 159 · cited 1×
“Recently, Peutz-Jeghers syndrome, single nucleotide polymorphisms (SNPs), hereditary pancreatitis, and a 5-10% family history of PC have also been added as PC risk factors [16, 35, 39].”
BackgroundVasen, H. F. A., Wasser, M., van Mil, A., Tollenaar, R. A., Konstantinovski, M., Gruis, N. A., Bergman, W., Hes, F. J., Hommes, D. W., Offerhaus, G. J. A., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.048 · Cited by 152
Cited by
Madhavan, B., Yue, S., Galli, U., Rana, S., Gross, W., Müller, M., Giese, N. A., Kalthoff, H., Becker, T., Büchler, M. W., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29324 · Cited by 495
Imaging diagnosis of pancreatic cancer: A state-of-the-art review
Lee, E. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i24.7864 · Cited by 401
Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection
Fahrmann, J. F., Schmidt, C. M., Mao, X., Irajizad, E., Loftus, M., Zhang, J., Patel, N., Vykoukal, J., Dennison, J. B., Long, J. P., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.052 · Cited by 208
A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer
Fahrmann, J. F., Bantis, L. E., Capello, M., Scelo, G., Dennison, J. B., Patel, N., Murage, E., Vykoukal, J., Kundnani, D. L., Foretova, L., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy126 · Cited by 115
Modulation of Glycan Recognition by Clustered Saccharide Patches
(2014) · International Review of Cell and Molecular Biology · doi:10.1016/b978-0-12-800097-7.00003-8 · Cited by 84
“SLe is the canonical epitope for cancer/carbohydrate antigen 19-9 (CA 19-9), and is used as a biomarker for cancer diagnostics (Bhat et al., 2012; Molina et al., 2012).”
Background
Metadata
- Authors
- Bhat, K., Wang, F., Ma, Q., Li, Q., Mallik, S., Hsieh, T.-C., & Wu, E.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-04-01
- Volume
- 18
- Issue
- 17
- Pages
- 2439-2451
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2121490159
- Cited by
- 72
- References
- 11
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.